Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast 2025

  • ID: 4436376
  • Drug Pipelines
  • 136 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Avexis
  • Biogen, Inc
  • Cytokinetics, Inc.
  • Hoffmann-La Roche
  • Novartis Pharmaceuticals
  • MORE
Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast 2025 provides an overview of the Spinal Muscular Atrophy, epidemiology and market trend of the Spinal Muscular Atrophy for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Spinal Muscular Atrophy from 2017 to 2025 segmented by seven major markets. In addition, The report also includes the forecasted epidemiology of Spinal Muscular Atrophy till 2025. The report also highlights the market drivers, market barriers and unmet medical needs.

Our report provides the type specific prevalent population of SMA i.e. Type I, Type II, Type III and Type IV. According to research, the prevalent population of Spinal Muscular Atrophy was estimated to be 38,900 in 2017. High prevalent cases were observed in EU5 as compared to US and Japan.

There was no approved drug for SMA until the Launch of Spinraza (Biogen, Inc.). This will significantly impact the otherwise stagnant market of SMA. Emerging Drugs CK-2127107 (Cytokinetics Inc.), RG7916 (Hoffmann-La Roche), AVXS-101 (Avexis), Olesoxime (Hoffmann-La Roche) and LMI070 (Novartis Pharmaceuticals) shall further drive the SMA market during the study period 2017-2025.

United States contributes the major share of CD market as compared to EU5 countries and Japan. The therapeutic market of CD in 7MM is expected to be USD 825 Million in 2017. This is expected to increase for the study period i.e., 2015-2025.

Key Coverage and Benefits:
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Spinal Muscular Atrophy market.
  • Organize sales and marketing efforts by identifying the best opportunities for Spinal Muscular Atrophy in US, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
  • The report provides historical as well as forecasted epidemiology of Spinal Muscular Atrophy in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2025.
  • To understand the future market competition in the global Spinal Muscular Atrophy market and Insightful review of the key market drivers and barriers.
  • To understand the regulatory scenario in major markets.
  • The report also covers the detailed global historical and forecasted Spinal Muscular Atrophy market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017-2025.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Avexis
  • Biogen, Inc
  • Cytokinetics, Inc.
  • Hoffmann-La Roche
  • Novartis Pharmaceuticals
  • MORE
1. Report Summary

2. Spinal Muscular Atrophy (SMA) Market Overview at a Glance
2.1. Total Market Share Distribution of SMA for 7 MM in 2017
2.2. Total Market Share Distribution of SMA for 7 MM in 2025

3. Spinal Muscular Atrophy: Background & Overview
3.1. Introduction
3.2. Classification
3.3. Causes
3.4. Pathophysiology
3.5. Symptoms
3.6. Diagnosis

4. Epidemiology and Patient Population

5. Population and Forecast Parameters
5.1. Key Notes

6. Prevalent Population of SMA in 7MM
6.1. Diagnosed Prevalent SMA Cases in 2017
6.2. Diagnosed Prevalent SMA Cases in 2025

7. United States
7.1. Diagnosed Prevalent Cases of SMA in United States

8. EU5 (Germany, France, UK, Spain & Italy)

9. Germany
9.1. Diagnosed Prevalent Cases of SMA in Germany

10. France
10.1. Diagnosed Prevalent Cases of SMA in France

11. United Kingdom
11.1. Diagnosed Prevalent Cases of SMA in UK

12. Spain
12.1. Diagnosed Prevalent Cases of SMA in Spain

13. Italy
13.1. Diagnosed Prevalent Cases of SMA in Italy

14. Japan
14.1. Diagnosed Prevalent Cases of SMA in Japan

15. Treatment Algorithm
15.1. Therapeutic strategies
15.2. Experts Opinions for Off-Label (Supportive Therapies) drugs
15.3. US Association Current Recommendations for SMA (Guidelines)
15.4. Europe Association Current Recommendations for SMA
15.5. Japan Association Current Recommendations for SMA

16. Unmet needs

17. Marketed Drugs List

18. Marketed Drugs
18.1. Spinraza (nusinersen): Biogen, Inc.
18.1.1. Drug Description
18.1.2. Mechanism of Action
18.1.3. Regulatory Milestones
18.1.4. Advantages & Disadvantages
18.1.5. Safety and Efficacy
18.1.6. Product Profile
18.1.7. Drug Sales

19. Emerging Drugs
19.1. Key Cross Competition
19.2. AVXS-101: Avexis
19.2.1. Regulatory Milestones
19.2.2. Clinical Development
19.2.3. Ongoing Trials Information
19.2.4. Safety and Efficacy
19.2.5. Advantages and Disadvantages
19.2.6. Product Profile
19.2.7. AVXS-101 Market analysis
19.3. LMI070: Novartis Pharmaceuticals
19.3.1. Clinical Development
19.3.2. Ongoing Trials Information
19.3.3. Safety and Efficacy
19.3.4. Advantages and Disadvantages
19.3.5. Product Profile
19.3.6. LMI070 Market analysis
19.4. CK-2127107: Cytokinetics, Inc.
19.4.1. Regulatory Milestones
19.4.2. Other development activities
19.4.3. Clinical Development
19.4.4. Ongoing Trials Information
19.4.5. Safety and Efficacy
19.4.6. Advantages and Disadvantages
19.4.7. Product Profile
19.4.8. CK-2127107 Market analysis
19.5. RG7916: Hoffmann-La Roche
19.5.1. Regulatory Milestones
19.5.2. Other development activities
19.5.3. Clinical Development
19.5.4. Ongoing Trials Information
19.5.5. Safety and Efficacy
19.5.6. Advantages and Disadvantages
19.5.7. Product Profile
19.5.8. RG7916 Market analysis
19.6. Olesoxime (TRO19622): Hoffmann-La Roche
19.6.1. Regulatory Milestones
19.6.2. Other development activities
19.6.3. Clinical Development
19.6.4. Ongoing Trials Information
19.6.5. Safety and Efficacy
19.6.6. Advantages and Disadvantages
19.6.7. Product Profile
19.7. Other Emerging Therapies

20. Market Size
20.1. Key Findings

21. Global SMA Market Analysis
21.1. Overview of Global SMA Market (2017-2025)
21.2. Existing and Upcoming Therapies
21.3. Total Market Size of SMA for 7 MM in 2017-2025
21.4. Total Market Size of SMA in 7MM by Therapies
21.5. Total Patient Share of SMA in 7MM by Therapies

22. United States
22.1. Trends of Existing Therapy
22.2. Upcoming Therapies and Their Impact on Market
22.3. Forecasted Market Size of SMA
22.4. Total Market Size of SMA in the US by Therapies
22.5. Total Patient Share of SMA in the US by Therapies

23. Europe
23.1. Trends of Existing Therapy
23.2. Upcoming Therapies and Their Impact on Market
23.3. Forecasted Market Size of SMA in EU5
23.4. Total Market Size of SMA in EU5 by Therapies
23.5. Total Patient Share of SMA in EU5 by Therapies

24. Germany
24.1. Market Size of SMA in Germany
24.2. Total Market Size of SMA in Germany by Therapies
24.3. Total Patient Share of SMA in Germany by Therapies

25. France
25.1. Market Size of SMA in France
25.2. Total Market Size of SMA in France by Therapies
25.3. Total Patient Share of SMA in France by Therapies

26. United Kingdom
26.1. Market Size of SMA in UK
26.2. Total Market Size of SMA in the UK by Therapies
26.3. Total Patient Share of SMA in France by Therapies

27. Spain
27.1. Market Size of SMA in Spain
27.2. Total Market Size of SMA in Spain by Therapies
27.3. Total Patient Share of SMA in Spain by Therapies

28. Italy
28.1. Market Size of SMA in Italy
28.2. Total Market Size of SMA in Italy by Therapies
28.3. Total Patient Share of SMA in Italy by Therapies

29. Japan
29.1. Market Size of SMA in Japan
29.2. Total Market Size of SMA in Japan by Therapies
29.3. Total Patient Share of SMA in Japan by Therapies

30. Market Drivers and Barriers

31. Appendix

32. Report Methodology
32.1. Sources Used

33. Consulting Services

34. Disclaimer

35. About

List of Tables
Table 1: Types of SMA linked to Chromosome-5
Table 2: Diagnosed Prevalent Cases of SMA in United States, (2017-2025)
Table 3: Diagnosed Prevalent Cases of SMA in Germany, (2017-2025)
Table 4: Diagnosed Prevalent Cases of SMA in France, (2017-2025)
Table 5: Diagnosed Prevalent Cases of SMA in UK, (2017-2025)
Table 6: Diagnosed Prevalent Cases of SMA in Spain, (2017-2025)
Table 7: Diagnosed Prevalent Cases of SMA in Italy, (2017-2025)
Table 8: Diagnosed Prevalent Cases of SMA in Japan (2017-2025)
Table 9: United States Association Current Recommendations for SMA
Table 10: European Association Current Recommendations for SMA
Table 11: Japanese Association Current Recommendations for SMA
Table 12: List of Marketed Drugs for SMA
Table 13: Market Size of SMA in 7MM (USD Million) (2017-2025)
Table 14: 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 15: 7MM Drug-Specific Patient Share of SMA, (2017-2025)
Table 16: United States Market Size of SMA in USD Million, (2017-2025)
Table 17: United States Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 18: United States Drug-Specific Patient Share of SMA, (2017-2025)
Table 19: EU5 Market Size of SMA in USD Million, (2017-2025)
Table 20: EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 21: EU5 Drug-Specific Patient Share of SMA, (2017-2025)
Table 22: Germany Market Size of SMA in USD Million, (2017-2025)
Table 23: Germany Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 24: Germany Drug-Specific Patient Share of SMA, (2017-2025)
Table 25: France Market Size of SMA in USD Million, (2017-2025)
Table 26: France Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 27: France Drug-Specific Patient Share of SMA, (2017-2025)
Table 28: UK Market Size of SMA in USD Million, (2017-2025)
Table 29: UK Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 30: France Drug-Specific Patient Share of SMA, (2017-2025)
Table 31: Spain Market Size of SMA in USD Million, (2017-2025)
Table 32: Spain Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 33: Spain Drug-Specific Patient Share of SMA, (2017-2025)
Table 34: Italy Market Size of SMA in USD Million, (2017-2025)
Table 35: Italy Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 36: Italy Drug-Specific Patient Share of SMA, (2017-2025)
Table 37: Japan Market Size of SMA in USD Million, (2017-2025)
Table 38: Japan Drug-Specific Market Size of SMA in USD Million, (2017-2025)
Table 39: Drug-Specific Patient Share of SMA, (2017-2025)

List of Figures
Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2025
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2025)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2025)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2025)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2025)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2025)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2025)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2025)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2025)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2025)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2025)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2025)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2025)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2025)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2025)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2025)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2025)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2025)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2025)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2025)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2025)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2025)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2025)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2025)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2025)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2025)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2025)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2025)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2025)
Figure 38: Total Market Size of SMA for 7 MM in USD Million, (2017-2025)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2025)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2025)
Figure 41: United States Market Size of SMA in USD Million, (2017-2025)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2025)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2025)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2025)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2025)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2025)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2025)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2025)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2025)
Figure 50: France Market Size of SMA in USD Million, (2017-2025)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2025)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2025)
Figure 53: UK Market Size of SMA in USD Million, (2017-2025)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2025)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2025)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2025)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2025)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2025)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2025)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2025)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2025)
Figure 62: Japan Market Size of SMA in USD Million (2017-2025)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2025)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2025)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Biogen, Inc
  • Hoffmann-La Roche
  • Cytokinetics, Inc.
  • Novartis Pharmaceuticals
  • Avexis
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll